Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model

Mary J. Heeb; Ulla Marzec; Andras Gruber; Stephen R. Hanson

doi:10.1160/TH11-10-0699

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2012; 107(04): 690-698
DOI: 10.1160/TH11-10-0699

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Antithrombotic activity of protein S infused without activated protein C in a baboon thrombosis model

Autoren

Mary J. Heeb

¹Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
Ulla Marzec

²Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA
Andras Gruber

²Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA
Stephen R. Hanson

²Department of Biomedical Engineering, Oregon Health and Science University, Portland, Oregon, USA

Abstract

Summary

Protein S (ProS) is an essential plasma protein that enhances the anticoagulant activity of activated protein C (APC). In vitro, purified native human Zn²⁺-containing ProS also exerts direct anticoagulant activity by inhibiting prothrombinase and extrinsic FXase activities independently of APC. We investigated antithrombotic effects of ProS infused without APC in a baboon shunt model of thrombogenesis that employs a device consisting of arterial and venous shear flow segments. In in vitro experiments, the Zn²⁺-containing human ProS used for the studies displayed >10-fold higher prothrombinase inhibitory activity and anticoagulant activity in tissue factor-stimulated plasma, and four-fold higher inhibition of the intrinsic pathway than the Zn²⁺-deficient ProS used. In the thrombosis model, ProS (33 μg/minute for 1 hour) or saline was infused locally; platelet and fibrin deposition in the shunt were measured over 2 hours. During experiments performed at 50 ml/minute blood flow, Zn²⁺-containing ProS inhibited platelet deposition 73–96% in arterialtype flow segments and 90–99% in venous-type flow segments; Zn²⁺-deficient ProS inhibited platelet deposition 52% in arterial-type flow segments and 65–73% in venous-type flow segments. At 100 ml/min blood flow rate, Zn²⁺-containing ProS inhibited platelet deposition by 39% and 73% in the respective segments; Zn²⁺-deficient ProS inhibited platelet deposition by 5% and 0% in the respective segments. Zn²⁺-containing ProS suppressed fibrin deposition by 67–90%. Systemic APC-independent ProS activity was significantly increased and thrombin-antithrombin complex levels were significantly decreased after infusion of ProS. Thus, infused human Zn²⁺-containing ProS is antithrombotic in primates, and may have therapeutic potential even in protein C-deficient human patients.

These studies were presented in part in abstract form at an oral presentation at the XXIth Congress of the International Society on Thrombosis and Haemo -stasis, Geneva, Switzerland, August 2007.

Keywords

Anticoagulants - platelets - protein S - thrombosis model

Volltext

Referenzen

References
1 Mahasandana C, Suvatte V, Marlar RA. et al. Neonatal purpura fulminans associated with homozygous protein S deficiency (Letter). Lancet 1990; 335: 61-62.
2 Schwarz H P, Fischer M, Hopmeier P. et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-1300.
3 Mahmoodi BK, Brouwer JL, Veeger NJ. et al. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 2008; 118: 1659-1667.
4 Burstyn-Cohen T, Heeb MJ, Lemke G. Lack of Protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis. J Clin Invest 2009; 119: 2942-2953.
5 Walker FJ. Regulation of activated protein C by a new protein. A possible function for bovine protein S. J Biol Chem 1980; 255: 5521-5524.
6 Heeb MJ, Mesters RM, Tans G. et al. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-2877.
7 Heeb MJ, Rosing J, Bakker HM. et al. Protein S binds to and inhibits factor Xa. Proc Natl Acad Sci USA 1994; 91: 2728-2732.
8 Hackeng TM, van't Veer C, Meijers JCM. et al. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem 1994; 269: 21051-21058.
9 Koppelman SJ, Hackeng TM, Sixma JJ. et al. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood 1995; 86: 1062-1071.
10 Fernandes NL, Mosnier LO, Tonnu L. et al. Zinc-containing protein S inhibits extrinsic factor X activating complex independently of tissue factor pathway inhibitor. Journal of Thrombosis and Haemostasis 2010; 08: 1976-1985.
11 Takeyama M, Nogami K, Saenko EL. et al. Identification of a protein S-interactive site within the A2 domain of the factor VIII heavy chain. Thromb Haemost 2009; 102: 645-655.
12 Heeb MJ, Prashun D, Griffin JH. et al. Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. FASEB J 2009; 23: 2244-2253.
13 Heeb MJ, Radtke K-P, Fernandez JA. et al. Plasma contains protein S monomers and multimers with similar direct anticoagulant activity. J Thromb Haemost 2006; 04: 2215-2222.
14 Hackeng T, Sere KM, Tan s G. et al. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 2006; 103: 3106-3111.
15 Gruber A, Griffin JH, Harker L. et al. Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 1989; 73: 639-642.
16 Hanson SR, Griffin JH, Harker LA. et al. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. J Clin Invest 1993; 92: 2003-2012.
17 Scott NA, Nunes GL, King SB. et al. Local delivery of an antithrombin inhibits platelet-dependent thrombosis. Circulation 1994; 90: 1951-1955.
18 Matthay MA. Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 2001; 344: 759-762.
19 Grinnell BW, Walls JD, Marks C. et al. Gamma-Carboxylated isoforms of recombinant human protein S with different biologic properties. Blood 1990; 76: 2546-2554.
20 Markou C P, Lutostansky EM, Ku DN. et al. A novel method for efficient drug delivery. Ann Biomed Eng 1998; 26: 502-511.
21 Heeb MJ, Schuck P, Xu X. Protein S multimers and monomers each have direct anticoagulant activity. J Thromb Haemost 2006; 04: 385-391.
22 Fernandez JA, Heeb MJ, Xu X. et al. Species-specific anticoagulant and mitogenic activities of murine protein S. Haematologica 2009; 94: 1721-1731.
23 Sen P, Sahoo S, Pendurthi UR. et al. Zinc modulates the interaction of protein C and activated protein C with endothelial cell protein C receptor. J Biol Chem 2010; 285: 20410-20420.
24 Zhu T, Ubhayasekera W, Nickolaus N. et al. Zinc ions bind to and inhibit activated protein C. Thromb Haemost 2010; 104: 544-553.
25 Tanaka KA, Fernandez JA, Marzec UM. et al. Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. Br J Haematol 2006; 132: 197-203.
26 Ndonwi M, Broze Jr G. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 2008; 06: 1044-1046.
27 Kask L, Trouw LA, Dahlback B. et al. The C4b-binding protein-protein S complex inhibits the phagocytosis of apoptotic cells. J Biol Chem 2004; 279: 23869-23873.
28 Hurtado B, Munoz X, Recarte-Pelz P. et al. Expression of the vitamin K-dependent proteins GAS6 and protein S and the TAM receptor tyrosine kinases in human atherosclerotic carotid plaques. Thromb Haemost 2011; 105: 873-882.